MDxHealth now carries a refreshed fair value estimate of US$1.80, down from US$2.20, which marks about an 18% reduction in the central price target used in the latest analyst model. This shift reflects recent commentary that weighs progress in prostate cancer diagnostics and balance sheet clean up against dilution from new equity and questions about execution after the Resolve wind down. As you read on, you will see how these moving parts shape the evolving MDxHealth story and what to watch next.

Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value MDxHealth.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

• BTIG sees MDxHealth as a focused prostate cancer diagnostics company and describes it as a solid pure play in this space, even after revising its price target to US$2 from US$4.

• Lake Street highlights the PROMPT publication and the upcoming PROTECT readout as key clinical milestones for MDxHealth and says these events help support its positive stance on the stock.

🐻 Bearish Takeaways

• Both BTIG and Lake Street have reduced their MDxHealth price targets, with BTIG moving to US$2 from US$4 and Lake Street to US$3 from US$5, which signals more cautious valuation assumptions in their latest models.

• Lake Street points to dilution from the registered direct offering and BTIG notes the recent US$20m public stock offering, which leaves some investors focused on the impact of a higher share count and execution after the Resolve wind down.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!

We've flagged 4 risks for MDxHealth. See which could impact your investment.

How This Changes the Fair Value For MDxHealth

• Fair value in the model has moved from US$2.20 to US$1.80, which is a reduction of about 18% in the central valuation estimate for MDxHealth.

• Revenue growth used in the model has shifted from 8.29% to 8.78% for MDxHealth.

• Net profit margin has moved from 16.88% to 17.78% in the MDxHealth assumptions.

• The future P/E multiple has changed from 7.36x to 5.66x in the updated MDxHealth framework.

• The discount rate applied has moved from 10.86% to 11.01% in the MDxHealth model.

Never Miss an Update: Follow The Narrative

Narratives link MDxHealth's business story to a financial forecast and fair value, so you can see how clinical, commercial and balance sheet events fit together. They update over time when new information is added to the MDxHealth investment case.